4.70
price up icon4.21%   0.19
after-market After Hours: 4.70
loading
2 Seventy Bio Inc stock is traded at $4.70, with a volume of 268.18K. It is up +4.21% in the last 24 hours and down -2.29% over the past month. 2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
See More
Previous Close:
$4.51
Open:
$4.6
24h Volume:
268.18K
Relative Volume:
0.91
Market Cap:
$237.41M
Revenue:
$100.39M
Net Income/Loss:
$-217.57M
P/E Ratio:
-1.138
EPS:
-4.13
Net Cash Flow:
$-180.72M
1W Performance:
-2.29%
1M Performance:
-2.29%
6M Performance:
-1.26%
1Y Performance:
+88.00%
1-Day Range:
Value
$4.47
$4.80
1-Week Range:
Value
$4.34
$4.80
52-Week Range:
Value
$1.535
$6.40

2 Seventy Bio Inc Stock (TSVT) Company Profile

Name
Name
2 Seventy Bio Inc
Name
Phone
339-499-9300
Name
Address
60 BINNEY STREET, CAMBRIDGE
Name
Employee
425
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
TSVT's Discussions on Twitter

2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-13-23 Downgrade Goldman Buy → Neutral
Sep-12-23 Downgrade Guggenheim Buy → Neutral
Jul-28-23 Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-31-22 Initiated Guggenheim Buy
May-02-22 Initiated Goldman Buy
Feb-10-22 Initiated SVB Leerink Outperform
Jan-06-22 Initiated Cowen Outperform
Nov-09-21 Initiated Canaccord Genuity Buy
Nov-08-21 Initiated Morgan Stanley Overweight
Nov-08-21 Initiated Wedbush Outperform
View All

2 Seventy Bio Inc Stock (TSVT) Latest News

pulisher
Nov 01, 2024

Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace

Nov 01, 2024
pulisher
Oct 22, 2024

2seventy bio, Inc. (NASDAQ:TSVT) Shares Sold by Exchange Traded Concepts LLC - Defense World

Oct 22, 2024
pulisher
Oct 17, 2024

BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS) - Yahoo Finance

Oct 17, 2024
pulisher
Oct 14, 2024

Dimensional Fund Advisors LP Sells 24,371 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

Oct 14, 2024
pulisher
Oct 09, 2024

TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Oct 09, 2024
pulisher
Sep 25, 2024

2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance - Business Wire

Sep 25, 2024
pulisher
Sep 24, 2024

Seven Eight Capital LP Makes New $197,000 Investment in Beyond, Inc. (NYSE:BYON) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Q&A: Athens legends Five Eight and the makers of their new documentary film, "Weirdo" - Online Athens

Sep 24, 2024
pulisher
Sep 22, 2024

Four killed, dozens injured in Alabama mass shooting - Daily Sun

Sep 22, 2024
pulisher
Sep 22, 2024

Seven Eight Capital LP Sells 536 Shares of Dell Technologies Inc. (NYSE:DELL) - Defense World

Sep 22, 2024
pulisher
Sep 22, 2024

Four dead, 17 others shot in Birmingham mass shooting - WJLA

Sep 22, 2024
pulisher
Sep 22, 2024

Five Below, Inc. (NASDAQ:FIVE) Stake Raised by Teca Partners LP - Defense World

Sep 22, 2024
pulisher
Sep 22, 2024

Four killed, over 20 injured in Birmingham, Alabama shooting - Thaiger World

Sep 22, 2024
pulisher
Sep 22, 2024

At least four dead and dozens injured in shootout with multiple assailants in the United States - Top Buzz Times

Sep 22, 2024
pulisher
Sep 22, 2024

Four people dead and dozens injured in US mass shooting horror - Express

Sep 22, 2024
pulisher
Sep 21, 2024

Analyst bullish on Tectonic's TX45 ahead of full trial results presentation at AHA - Investing.com India

Sep 21, 2024
pulisher
Sep 19, 2024

Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45 - GlobeNewswire

Sep 19, 2024
pulisher
Sep 19, 2024

Hedge fund Two Sigma in settlement talks with US SEC, WSJ reports - XM

Sep 19, 2024
pulisher
Sep 19, 2024

US data: key federal and state updates (13 – 19 Sep) - Lexology

Sep 19, 2024
pulisher
Sep 10, 2024

The LYCRA Company Presents Seminars on Sustainable Elastane Solutions at the 63rd Dornbirn Global Fiber Congress - Via Ritzau

Sep 10, 2024
pulisher
Aug 18, 2024

Jessica Snow Sells 7,816 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock - Defense World

Aug 18, 2024
pulisher
Aug 10, 2024

2seventy bio, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Yahoo Finance

Aug 10, 2024
pulisher
Aug 07, 2024

2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress - Business Wire

Aug 07, 2024
pulisher
Aug 05, 2024

2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024 - Business Wire

Aug 05, 2024
pulisher
Jul 29, 2024

Biopharma Layoff Tracker 2024: Cue, Anokion, GlycoMimetics and More Cut Staff - BioSpace

Jul 29, 2024
pulisher
Jul 17, 2024

Annovis Bio Inc (ANVS-N) QuotePress Release - The Globe and Mail

Jul 17, 2024
pulisher
Jul 14, 2024

Royals select Florida 2-way star Caglianone 6th overall - theScore

Jul 14, 2024
pulisher
Jul 13, 2024

Biopharma Layoff Tracker 2024: Spark, Novartis, Indivior and More Cut Staff - BioSpace

Jul 13, 2024

2 Seventy Bio Inc Stock (TSVT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):